The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428
Open accessAbstract
Methamphetamine and methcathinone are psychostimulant drugs with high potential for abuse. In animals, methamphetamine and related drugs are known to damage brain dopamine (DA) neurons, and this damage has recently been shown to be detectable in living nonhuman primates by means of positron emission tomography (PET) with [11C]WIN-35,428, a DA transporter (DAT) ligand. The present studies determined whether living humans with a history of methamphetamine or methcathinone abuse showed evidence of lasting decrements in brain DAT density. PET studies were performed in 10 control subjects, six abstinent methamphetamine users, four abstinent methcathinone users, and three patients with Parkinson's disease (PD). On average, subjects had abstained from amphetamine use for approximately 3 years. Before PET studies, all subjects underwent urine and blood toxicology screens to rule out recent drug use. Compared with controls, abstinent methamphetamine and methcathinone users had significant decreases in DAT density in the caudate nucleus (-23 and -24%, respectively) and putamen (-25 and -16%, respectively). Larger decreases in DAT density were evident in patients with PD (47 and 68% in caudate and putamen, respectively). Neither methamphetamine nor methcathinone users showed clinical signs of parkinsonism. Persistent reductions of DAT density in methamphetamine and methcathinone users are suggestive of loss of DAT or loss of DA terminals and raise the possibility that as these individuals age, they may be at increased risk for the development of parkinsonism or neuropsychiatric conditions in which brain DA neurons have been implicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alternatively, studies in methamphetamine abusers show a consistent and long lasting decrease in the dopamine transporter, which is the main target of this drug (Chou et al., 2007; Johanson et al., 2006; McCann et al., 1998; McCann et al., 2008; Sekine et al., 2001; Volkow et al., 2001b).”
From Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity (2014) · cites this paper as McCann et al., 1998
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K. S., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,945 · cited 1×
“…reduction in [ 11 C]WIN-35,428 BP in the putamen compared with the caudate nucleus is in keeping with previous observations of greater DA terminal loss in the putamen than in the caudate of patients with PD (Kish et al., 1988; Tedroff et al., 1988; Kaufman and Madras, 1991; Frost et al., 1993).”
ResultDopamine (3-hydroxytyramine) and brain function.
Hornykiewicz, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,389 · cited 2×
“…more severe, decreases in [ 11 C]W I N-35,428 binding are evident in the striata of patients with PD (Kaufman and Madras, 1991; Frost et al., 1993; Table 3), a neurodegenerative disorder in which nigrostriatal DA neuronal degeneration is well documented (Hornykiewicz, 1966; K ish et al., 1988).”
BackgroundStriatal dopamine nerve terminal markers in human, chronic methamphetamine users
Wilson, J. M., Kalasinsky, K. S., Levey, A. I., Bergeron, C., Reiber, G. D., Anthony, R. M., Schmunk, G. A., Shannak, K. S., Haycock, J. W., & Kish, S. J. (1996) · Nature Medicine · doi:10.1038/nm0696-699 · Cited by 718 · cited 2×
“…for detecting severe DA cell loss, such as in PD (Hornykiewicz, 1966; Tedroff et al., 1988; Wilson et al., 1996b), they appear to be less sensitive for detecting milder degrees of nigrostriatal DA injury, such as that in olivopontocerebellar atrophy (Zhong et al., 1995; Wilson et al., 1996b).”
BackgroundWagner, G. C., Ricaurte, G. A., Seiden, L. S., Schuster, C. R., Miller, R. J., & Westley, J. (1980) · Brain Research · doi:10.1016/0006-8993(80)91265-2 · Cited by 523 · cited 3×
“After administration of methamphetamine or methcathinone, animals develop long-lasting decreases in brain DA and 5-HT axonal markers, including the neurotransmitters themselves (i.e., DA and 5-HT), their rate-limiting synthetic enzymes (tyrosine hydroxylase and tryptophan hydroxylase), and their transporter sites (Sei…”
BackgroundRole for Excitatory Amino Acids in Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity
Sonsalla, P. K., Nicklas, W. J., & Heikkila, R. E. (1989) · Science · doi:10.1126/science.2563176 · Cited by 483 · cited 1×
“, two to four times at 2 hr intervals) (Sonsalla et al., 1989; Melega et al., 1993).”
BackgroundDopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain
Ricaurte, G. A., Guillery, R. W., Seiden, L. S., Schuster, C. R., & Moore, R. Y. (1982) · Brain Research · doi:10.1016/0006-8993(82)90198-6 · Cited by 479 · cited 1×
“, 1996; Hirata and Cadet, 1997) but not in rats (Ricaurte et al., 1982) or monkeys (Woolverton et al.”
BackgroundHotchkiss, A. J., & Gibb, J. W. (1980) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32165-8 · Cited by 443
Frost, J. J., Rosier, A., Reich, S. G., Smith, J. S., Ehlers, M., Snyder, S. H., Ravert, H. T., & Dannals, R. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340331 · Cited by 320 · cited 2×
“…reduction in [ 11 C]WIN-35,428 BP in the putamen compared with the caudate nucleus is in keeping with previous observations of greater DA terminal loss in the putamen than in the caudate of patients with PD (Kish et al., 1988; Tedroff et al., 1988; Kaufman and Madras, 1991; Frost et al., 1993).”
BackgroundResultPresynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Frey, K. A., Koeppe, R. A., Kilbourn, M. R., Borght, T. M. V., Albin, R. L., Gilman, S., & Kuhl, D. E. (1996) · Annals of Neurology · doi:10.1002/ana.410400609 · Cited by 314 · cited 4×
“Although agerelated reductions in the DAT are known to occur (Evans et al., 1991; Volkow et al., 1994; van Dyck et al., 1995; Frey et al., 1996), the reported age-related decreases are not of the degree observed in the present study nor do they occur from ages 30 to 37, the mean ages of…”
BackgroundInfluentialLong-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys
Seiden, L. S., Fischman, M. W., & Schuster, C. R. (1976) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(76)90030-2 · Cited by 307 · cited 1×
“, DA and 5-HT), their rate-limiting synthetic enzymes (tyrosine hydroxylase and tryptophan hydroxylase), and their transporter sites (Seiden et al., 1976; Wagner et al., 1979, 1980a,b, 1983; Hotchkiss and Gibb, 1980; Levine et al., 1980; Steranka and Sanders-Bush, 1980; Bakhit et al., 1981; Woolverton et al., 1989; Gy…”
Background
Research works printed but not linked: 5
- Brill, 1969, The rise and fall of a methamphetamine epidemic., Semin Psychiatry, 1, 179
- Lukas SE (1997) Proceedings of the national consensus meeting on the use, abuse and sequelae of abuse of methamphetamine with implications for prevention, treatment and research. DHHS Publication SMA. 96–8013. (USDHHS, Rockville, MD).
- Melega, 1993, FDOPA-PET studies show neurotoxic effects of low-dose amphetamine in monkeys., Soc Neurosci Abstr, 19, 822
- Tolliver, 1995, Methcathinone: a new amphetamine-like drug of abuse., Natl Inst Drug Abuse Res Monogr Ser, 153, 406
- U.S Department of Justice, Drug Enforcement Administration (1994) Methcathinone (CAT). Drug intelligence bulletin. Washington, D.C.: U.S. Department of Justice, February.
Cited by
Sorted by citations
Items 201–300 of 604
Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats
Munzar, P., & Goldberg, S. R. (2000) · Psychopharmacology · doi:10.1007/s002130050044 · Cited by 63
“Chronic methamphetamine abuse leads to long lasting reductions in brain dopamine transporter density in humans, as revealed by post-mortem analysis (Wilson et al. 1996) as well as by positron emission tomography in chronic methamphetamine users ( McCann et al. 1998 ).”
BackgroundMethamphetamine and sleep impairments: neurobehavioral correlates and molecular mechanisms
Vrajová, M., Šlamberová, R., Höschl, C., & Ovsepian, S. V. (2021) · SLEEP · doi:10.1093/sleep/zsab001 · Cited by 66
Newton, T. F., Reid, M. S., Garza, R. D. L., Mahoney, J. J., Abad, A., Condos, R., Palamar, J. J., Halkitis, P. N., Mojisak, J., Anderson, A., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009097 · Cited by 61
“These include reductions in dopamine transporter (DAT) expression (Johanson et al., 2006 ; McCann et al., 1998 ; Sekine et al., 2001 ; Volkow et al., 2001b) and DA D2 receptor binding availability (Volkow et al.”
Nelson, M. E., Bryant, S. M., & Aks, S. E. (2014) · Disease-a-Month · doi:10.1016/j.disamonth.2014.01.001 · Cited by 61
“had decreased dopamine transporters on positron emission tomography scans similar to methamphetamine users and patients with Parkinson disease, suggesting the potential risk for long-term neuropsychiatric problems.(122)”
BackgroundTeucher, U. (2009) · British Journal of Psychology · doi:10.1348/000712609x435742 · Cited by 61
Interactions of HIV and methamphetamine: Cellular and molecular mechanisms of toxicity potentiation
Cadet, J. L., & Krasnova, I. N. (2007) · Neurotoxicity Research · doi:10.1007/bf03033915 · Cited by 59
Zhu, J., Wang, X., Angulo, N., & Angulo, J. A. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2005.05.014 · Cited by 60
“These reductions may be due to toxicity (fewer dopamine terminals) rather than a neuroadaptation (diminished number of dopamine transporter sites against an unchanged number of dopamine terminals) since Positron Emission Tomography scanning involving METH abusers showed reduced levels of dopamine transporters in the c…”
BackgroundKousik, S. M., Carvey, P. M., & Napier, T. C. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12628 · Cited by 60
“…from Meth self-administration in rats (present study; McFadden et al., 2012) is more reminiscent of what is reported in human imaging studies, wherein Meth abusers abstinent from drugs for an average of 3 years show approximately a 30% loss in pre-synaptic striatal DA markers (McCann et al., 1998).”
ResultNeurotoxicology of Synthetic Cathinone Analogs
Angoa‐Pérez, M., Anneken, J. H., & Kuhn, D. M. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_21 · Cited by 60
“In humans, persistent reductions of DAT density have been reported using PET in methcathinone users and are suggestive of loss of DAT or loss of DA terminals [10, 77].”
Harvey, D. C., Laćan, G., & Melega, W. P. (2000) · Experimental Brain Research · doi:10.1007/s002210000386 · Cited by 60
“In those METH users, the pattern of deficit was similar to the one obtained in the animal studies, but the effect was of lower magnitude ( McCann et al. 1998 ).”
ResultPeripheral Ammonia as a Mediator of Methamphetamine Neurotoxicity
Halpin, L. E., & Yamamoto, B. K. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2530-12.2012 · Cited by 58
“This dose of METH was chosen because it produces long-term neuronal damage similar to what is seen in studies of human METH users (McCann et al., 1998).”
BackgroundGraham, D. L., Noailles, P.-A. H., & Cadet, J. L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05269.x · Cited by 58
Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers
Newton, T. F., Kalechstein, A. D., Hardy, D. J., Cook, I. A., Nestor, L. J., Ling, W. W., & Leuchter, A. F. (2003) · Clinical Neurophysiology · doi:10.1016/s1388-2457(03)00314-6 · Cited by 61
“…al., 1996), a series of studies have examined the neurobiological consequences of methamphetamine dependence in vivo using neuroimaging (Chang et al., 2002; Ernst et al., 2000; Fowler et al., 2001; McCann et al., 1998; Sekine et al., 2001), and using quantitative EEG (QEEG) (Newton et al., 2003).”
MethodNeurotoxicity following chronic intravenous use of “Russian Cocktail”
Varlıbaş, F., DELİPOYRAZ, İ., Yüksel, G. A., Filiz, G., Tireli, H., & Geçim, N. O. (2009) · Clinical Toxicology · doi:10.1080/15563650802010388 · Cited by 57
“In a study of methcathinone users, positron emission tomography found decreased densities of dopamine uptake transporter (6).”
BackgroundSegal, D. S., Kuczenski, R. T., O’Neil, M. L., Melega, W. P., & Cho, A. K. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2188-4 · Cited by 57
Ammonia Mediates Methamphetamine-Induced Increases in Glutamate and Excitotoxicity
Halpin, L. E., Northrop, N. A., & Yamamoto, B. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.306 · Cited by 58
“This dosing paradigm models the concentration and binge paradigm reported in METH-dependent humans and produces longterm depletions of dopamine and serotonin terminals (Cruickshank and Dyer, 2009; McCann et al, 1998; McKetin et al, 2006; Ricaurte et al, 1982; Wagner et al, 1980).”
BackgroundSocial‐cognitive difficulties in former users of methamphetamine
Henry, J. D., Mazur, M., & Rendell, P. G. (2009) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.2009.tb00487.x · Cited by 57
Jan, R. K., Lin, J. C., Miles, S. W., Kydd, R. R., & Russell, B. (2012) · Brain Sciences · doi:10.3390/brainsci2040553 · Cited by 57
“effect of MA on monoaminergic transmission have reported decreased presynaptic DAT and postsynaptic D2 receptor availability in the striatum of people with MA dependence [34–38].”
BackgroundIn Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia
Taylor, S. F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00165-2 · Cited by 56
“1980) and living humans with a history of stimulant abuse have exhibited reduced binding to the dopamine transporter even after several years of abstinence (McCann et al. 1998).”
BackgroundYuan, J., Callahan, B. T., McCann, U. D., & Ricaurte, G. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00339.x · Cited by 56
van de Giessen, E., Hesse, S., Caan, M. W. A., Zientek, F., Dickson, J. C., Tossici-Bolt, L., Séra, T., Asenbaum, S., Guignard, R., Akdemir, Ü. Ö., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.011 · Cited by 55
Interactions of HIV and Drugs of Abuse
Hauser, K. F., & Knapp, P. E. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00009-9 · Cited by 58
“These effects may be enduring (McCann et al., 1998).”
Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors
Weingarten, P., & Zhou, Q. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00263.x · Cited by 55
O’Neil, M. L., Kuczenski, R. T., Segal, D. S., Cho, A. K., Laćan, G., & Melega, W. P. (2006) · Synapse · doi:10.1002/syn.20320 · Cited by 54
“Reductions in striatal DA phenotypic markers in human METH abusers have now been documented in several positron emission tomography (PET) imaging (McCann et al., 1998; Sekine et al., 2001; Volkow et al., 2001; Wang et al., 2004) and postmortem studies (Tong et al.”
BackgroundHoefer, M. M., Sánchez, A. B., Maung, R., de Rozieres, C. M., Catalan, I. C., Dowling, C. C., Thaney, V. E., Piña-Crespo, J., Zhang, D., Roberts, A. J., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.010 · Cited by 54
Churchwell, J. C., Carey, P. D., Ferrett, H. L., Stein, D. J., & Yurgelun-Todd, D. A. (2012) · Developmental Neuroscience · doi:10.1159/000337724 · Cited by 52
Proebstl, L., Kamp, F., Manz, K., Krause, D., Adorjan, K., Pogarell, O., Koller, G., Soyka, M., Falkai, P., & Kambeitz, J. (2019) · European psychiatry · doi:10.1016/j.eurpsy.2019.03.003 · Cited by 52
Yuan, J., Hatzidimitriou, G., Suthar, P., Mueller, M., McCann, U. D., & Ricaurte, G. A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096503 · Cited by 53
“Evidence of possible METH-induced DA neurotoxicity is also available in humans (McCann et al., 1998; Sekine et al., 2001; Volkow et al., 2001).”
BackgroundReneman, L., Majoie, C. B. L. M., Flick, H., & den Heeten, G. J. (2002) · PubMed Central · Cited by 53
Mephedrone: Public health risk, mechanisms of action, and behavioral effects
Dybdal‐Hargreaves, N. F., Holder, N. D., Ottoson, P. E., Sweeney, M. D., & Williams, T. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.024 · Cited by 52
NPS: Medical Consequences Associated with Their Intake
Schifano, F., Orsolini, L., Papanti, D., & Corkery, J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_15 · Cited by 56
LOONAM, T. M., Noailles, P., Yu, J., Zhu, J. P. Q., & Angulo, J. A. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00393-x · Cited by 52
Caligiuri, M. P., & Buitenhuys, C. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300859 · Cited by 52
“PET studies have shown up to a 25% reduction in DAT in the caudate and putamen among MA users (McCann et al, 1998; Volkow et al, 2001b).”
BackgroundFunctional and Structural Brain Changes Associated with Methamphetamine Abuse
Jan, R. K., Kydd, R. R., & Russell, B. R. (2012) · Brain Sciences · doi:10.3390/brainsci2040434 · Cited by 52
“Similar findings were reported in an earlier PET study using [(11)C]WIN-35,428, a DAT ligand, including reductions in DAT levels of 23% and 25% respectively in the caudate and putamen of MA abusers who had been abstinent for 3 years on average, relative to controls [97].”
BackgroundResultClinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure
Sikk, K., Taba, P., Haldre, S., Bergquist, J., Nyholm, D., Askmark, H., Danfors, T., Sørensen, J. C. H., Thurfjell, L., Raininko, R., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01189.x · Cited by 51
“In two Mn intoxicated rhesus monkeys, no significant changes were foundonFDGPET (25), but four humanswith mild manganism showed decreased cortical metabolism (6).”
BackgroundInfluentialNeuromechanism of Developing Methamphetamine Psychosis: A Neuroimaging Study
Iyo, M., Sekine, Y., & Mori, N. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1316.036 · Cited by 51
Lingford-Hughes, A. R., Davies, S., McIver, S. R., Williams, T. A., Daglish, M. R. C., & Nutt, D. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.209 · Cited by 51
Norman, L. R., Basso, M. R., Kumar, A., & Malow, R. M. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902020143 · Cited by 50
“Despite abstinence of three years, amphetamine abusers continue to show abnormally depleted amounts of dopamine in the caudate and putamen [156].”
BackgroundBehavioral genetic contributions to the study of addiction-related amphetamine effects
Phillips, T. J., Kamens, H. M., & Wheeler, J. M. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.10.008 · Cited by 51
“Neurotoxicity Brain alterations associated with chronic methamphetamine abuse have been documented in humans using imaging techniques (McCann et al., 1998; Volkow et al., 2001; Wang et al., 2004).”
MethodCreatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49
“Also, reductions in neurotransmitters, such as dopamine and serotonin, with methamphetamine use are well documented (McCann et al., 1998; Sekine et al., 2001; Volkow, Chang, Wang, Fowler, Leonido-Yee et al., 2001), as well as high rates of neuropsychiatric symptoms, including depression (Zweben et…”
BackgroundMonoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats
Byrnes-Blake, K. A., Laurenzana, E. M., Landes, R. D., Gentry, W. B., & Owens, S. M. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.08.016 · Cited by 49
Methamphetamine causes acute hyperthermia‐dependent liver damage
Halpin, L. E., Gunning, W. T., & Yamamoto, B. K. (2013) · Pharmacology Research & Perspectives · doi:10.1002/prp2.8 · Cited by 49
“This dose simulates the concentration and binge dosing paradigm reported in METH-dependent humans and produces the same long-term neuronal damage seen in humans after METH exposure (McCann et al. 1998; Volkow et al. 2001; McKetin et al. 2006; Cruickshank and Dyer 2009).”
BackgroundfMRI of Cocaine Self-Administration in Macaques Reveals Functional Inhibition of Basal Ganglia
Mandeville, J. B., Choi, J., Jarraya, B., Rosen, B. R., Jenkins, B. G., & Vanduffel, W. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.1 · Cited by 51
“…neurotransporters, the fMRI spatial response to cocaine in the NHP (Figure 3) most closely mimics the pattern of dopamine transporter density (McCann et al , 1998; Tsukada et al , 2001), dopamine D2 receptor density (Volkow et al , 1993; Nader et al , 2006), and cocaine binding (Fowler et al…”
White matter microstructural alterations in children with prenatal methamphetamine/polydrug exposure
Colby, J. B., Smith, L. M., O’Connor, M. J., Bookheimer, S. Y., Horn, J. D. V., & Sowell, E. R. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2012.04.017 · Cited by 48
“, 2004), and with the long-standing literature documenting striatal damage in adult MA abusers (McCann et al., 1998).”
BackgroundResultImaging the Neurochemistry of Alcohol and Substance Abuse
Martínez, D., Kim, J., Krystal, J. H., & Abi‐Dargham, A. (2007) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2007.07.004 · Cited by 50
“McCann and colleagues [75] reported on six methamphetamine abusers and four methcathinone”
BackgroundDavidson, C., Lee, T. H., & Ellinwood, E. H. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2004.11.004 · Cited by 49
Gervais, J., & Rouillard, C. (2000) · Synapse · doi:10.1002/(sici)1098-2396(20000315)35:4 · Cited by 109
Daberkow, D. P., Kesner, R., & Keefe, K. A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.03.010 · Cited by 49
“Interestingly, human METH users have shown partial reductions in dopamine transporter levels in the caudate and putamen (McCann et al., 1998; Volkow et al., 2001a), and these reductions have been shown to be correlated with impairments in motor function and memory tasks (Volkow et al., 2001b).”
BackgroundVesicular Integrity in Parkinson’s Disease
Alter, S. P., Lenzi, G. M., Bernstein, A. I., & Miller, G. W. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0362-3 · Cited by 50
Chen, S., Zhou, W., & Lai, M. (2024) · Brain Sciences · doi:10.3390/brainsci14040334 · Cited by 47
“Methcathinone users also display a reduction in DAT density [70].”
BackgroundWeinshenker, D., Ferrucci, M., Busceti, C. L., Biagioni, F., Lazzeri, G., Liles, L. C., Lenzi, P., Pasquali, L., Murri, L., Paparelli, A., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05145.x · Cited by 47
Glial reactivity in resistance to methamphetamine‐induced neurotoxicity
Friend, D. M., & Keefe, K. A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12201 · Cited by 49
Segal, D. S., & Kuczenski, R. T. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300865 · Cited by 47
“Clinical studies, in particular those using various neuroimaging techniques, have revealed potentially persistent or even permanent METH-induced neurobiological alterations (Wilson et al, 1996; McCann et al, 1998; Ernst et al, 2000; Sekine et al, 2001; Thompson et al, 2004).”
ResultAchat‐Mendes, C., Anderson, K. L., & Itzhak, Y. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301119 · Cited by 45
“In human METH abusers, selective reduction in the density of caudate and putamen DAT-binding sites has been associated with cognitive deficits (Chang et al, 2002; McCann et al, 1998; Volkow et al, 2001a, b).”
BackgroundNeuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND
Sánchez, A. B., & Kaul, M. (2017) · Brain Sciences · doi:10.3390/brainsci7030025 · Cited by 45
“The neuropathology resulting from METH abuse in humans includes a decrease of dopamine (DA) transporter (DAT) in cortex, caudate-putamen and other brain regions [182], reduction of DA and D2DA receptor in caudate-putamen [183,184], decreased density of serotonin transporter (5-HTT) in cortex [185], and abnormal glucos…”
BackgroundSalo, R. E., Buonocore, M. H., Leamon, M. H., Natsuaki, Y., Waters, C., Moore, C. D., Galloway, G. P., & NORDAHL, T. E. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.07.015 · Cited by 44
“One PET study reported evidence of sustained striatal DA transporter (DAT) abnormalities in long-term MA-dependent subjects who had remained abstinent for approximately 3 years (McCann et al., 1998).”
BackgroundMethamphetamine‐induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice
Kita, T., Matsunari, Y., Saraya, T., Shimada, K., O’Hara, K., Kubo, K., Wagner, G. C., & Nakashima, T. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00022-8 · Cited by 44
“In humans, the density of dopamine transporters was shown to be reduced in abstinent methamphetamine abusers using positron emission tomography, suggesting a long-term loss of dopamine transporters or terminals [28].”
BackgroundTrevizol, F., Roversi, K., Dias, V. T., Roversi, K., Pase, C. S., Barcelos, R. C. S., Benvegnú, D. M., Kuhn, F. T., Dolci, G. S., Ross, D. H., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.007 · Cited by 42
“In fact, AMPH is able to exacerbate the monoaminergic neurotransmission, whose metabolic consequence resulting from autoxidation and deamination is increased reactive species (RS) production (Graham et al., 1984; McCann et al., 1998).”
BackgroundKim, I.-S., Kim, Y., Song, H., Lee, J.-J., Kwon, D.-H., Lee, H. J., Kim, M., Yoo, D., & Chang, Y. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.12.002 · Cited by 43
N-acetyl-cysteine in the treatment of Parkinson’s disease. What are we waiting for?
Martı́nez, M. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.03.021 · Cited by 43
“On the other hand, recent studies using positron emission tomography suggested that chronic use of methamphetamine (METH) causes the reduction of dopamine transporter in the human brain, suggesting that this is the mechanism of neurotoxicity in humans [47].”
BackgroundTata, D. Α., Raudensky, J., & Yamamoto, B. K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05688.x · Cited by 41
Thomsen, G., Ziebell, M., Jensen, P. S., da Cunha‐Bang, S., Knudsen, G. M., & Pinborg, L. H. (2013) · Obesity · doi:10.1002/oby.20225 · Cited by 41
“In contrast to the findings in nicotine abuse, several studies have demonstrated a reduced DAT availability in subjects both actively abusing methamphetamine and in subjects detoxified for months (32,33).”
ResultLiterature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD
Advokat, C. D. (2007) · Journal of Attention Disorders · doi:10.1177/1087054706295605 · Cited by 44
“Recent results of imaging studies in human METH abusers show changes in dopaminergic neural pathways that are consistent with the observations in nonhuman models suggesting possible neurotoxicity (McCann et al., 1998; Thompson et al., 2004; Volkow et al., 2001).”
ResultCherner, M., Bousman, C., Everall, I., Barron, D. S., Letendre, S. L., Vaida, F., Atkinson, J. H., Heaton, R. K., Grant, I., & THE HNRC GROUP (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710000779 · Cited by 42
Cass, W. A., Peters, L. E., Harned, M. E., & Seroogy, K. B. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.024 · Cited by 44
Dong, J., de Montigny, C., & Blier, P. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19991215)34:4 · Cited by 16
O’Dell, S. J., Feinberg, L. M., & Marshall, J. F. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.08.022 · Cited by 41
Basterfield, C., Hester, R., & Bowden, S. C. (2019) · Neuropsychology · doi:10.1037/neu0000552 · Cited by 43
Chand, S., Gowen, A. M., Savine, M., Moore, D. Y., Clark, A. R., Huynh, W., Wu, N., Odegaard, K. E., Weyrich, L., Bevins, R. A., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12177 · Cited by 41
Belcher, A. M., O’Dell, S. J., & MARSHALL, J. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.02.025 · Cited by 41
Theodore, S., Cass, W. A., & Maragos, W. F. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.009 · Cited by 40
Heller, A., Bubula, N., Lew, R., Heller, B., & Won, L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29438-6 · Cited by 40
“A recent study in previous human methamphetamine users, abstinent for at least 3 years, showed that such individuals had significant reductions in DAT binding sites in the caudate and putamen (McCann et al., 1998).”
Chahid, Y., Sheikh, Z. H., Mitropoulos, M., & Booij, J. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06171-x · Cited by 39
Monoamine Reuptake Inhibitors in Parkinson’s Disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2015) · Parkinson s Disease · doi:10.1155/2015/609428 · Cited by 43
Owens, S. M., Atchley, W. T., Hambuchen, M. D., Peterson, E. C., & Gentry, W. B. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219370 · Cited by 39
“There are also reports of long-term neurotoxicity that continue long after the cessation of METH use [12-15].”
BackgroundLimitations of brain imaging in forensic psychiatry.
Reeves, D., Mills, M. J., Billick, S. B., & Brodie, J. D. (2003) · PubMed · Cited by 39
Peripheral ammonia and blood brain barrier structure and function after methamphetamine
Northrop, N. A., Halpin, L. E., & Yamamoto, B. K. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.018 · Cited by 38
“This dose of Meth was chosen based on previous studies that use this dosing regimen that illustrate long-term neuronal damage similar to what is seen in studies of human Meth users (McCann et al., 1998).”
Decreased cortical complexity in methamphetamine abusers
Yun, K., Park, H.-K., Kwon, D.-H., Kim, Y., Cho, S., Cho, H.-J., Peterson, B. S., & Jeong, J. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.07.009 · Cited by 38
“Recentneuroimaging studies have shown that long-term use of MA decreases the density of DA transporters in reward circuits (McCann et al., 1998; Sekine et al., 2001; Volkow et al., 2001a,b; Sekine et al., 2003) and the density of serotonin transporters in cortical regions (Sekine et al., 2006).”
BackgroundNeurobehavioural consequences of substance abuse and HIV infection
Basso, M. R., & Bornstein, R. A. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400306 · Cited by 38
Williams, M. T., Moran, M. S., & Vorhees, C. V. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.04.003 · Cited by 38
Garza, R. D. L., SHOPTAW, S. J., & Newton, T. F. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008456 · Cited by 38
“Users of Meth experience substantial medical and psychiatric morbidity, including dopamine (DA) system neurotoxicity (McCann et al., 1998 ; Sekine et al., 2001 ; Volkow et al., 2001) and grey-matter losses (Thompson et al., 2004), increased cardiovascular mortality (Karch et al., 1999), and higher…”
BackgroundAn Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence
Meredith, C. W., Jaffe, C., Yanasak, E., Cherrier, M., & Saxon, A. J. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399875 · Cited by 37
Baracz, S. J., Everett, N. A., & Cornish, J. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136132 · Cited by 39
“Chronic METH use can result in serious and pronounced cognitive [2], neurological [3,4] and psychiatric dysfunction [5,6] in addition to physical health problems [7,8].”
BackgroundCocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation
Seger, D. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.516263 · Cited by 37
Prenatal methamphetamine exposure is associated with reduced subcortical volumes in neonates
Warton, F. L., Meintjes, E. M., Warton, C. M. R., Molteno, C. D., Lindinger, N. M., Carter, R. C., Zöllei, L., Wintermark, P., Jacobson, J. L., van der Kouwe, A. J. W., et al. (2017) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2017.10.005 · Cited by 37
“, 2007) and human studies (Lee et al., 2009; McCann et al., 1998), and in mature neurons appears to involve the production of reactive oxygen species (ROS), activation of P53 and subsequent apoptosis, and dysfunction of mitochondria (Quinton and Yamamoto, 2006).”
BackgroundGraves, S. M., Schwarzschild, S. E., Tai, R., Chen, Y., & Surmeier, D. J. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105409 · Cited by 40
Parkinsonism in patients with a history of amphetamine exposure
Christine, C. W., Garwood, E. R., Schrock, L. E., Austin, D. E., & McCulloch, C. E. (2010) · Movement Disorders · doi:10.1002/mds.22915 · Cited by 37
Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm
Henry, B. L., Minassian, A., van Rhenen, M., Young, J. W., Geyer, M. A., & Perry, W. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2170-2 · Cited by 36
“…correspondence between MA use parameters and MA-related neuropsychological impairment (Chang et al. 2002; Cherner et al. 2010; Johanson et al. 2006; McCann et al. 1998); such findings may reflect poor self-report or individual variation in vulnerability to MA-induced neuro-cognitive injury…”
BackgroundStructural abnormality of substantia nigra induced by methamphetamine abuse
Rumpf, J., Albers, J., Fricke, C., Mueller, W. C., & Claßen, J. (2017) · Movement Disorders · doi:10.1002/mds.27205 · Cited by 36
Barrett, T., Xie, T., Piao, Y., Dillon‐Carter, O., Kargul, G. J., Lim, M. K., Chrest, F. J., Wersto, R. P., Rowley, D. L., Juhaszova, M., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0423 · Cited by 36
“Methamphetamine (METH) is a potent psychomotor stimulant drug that has high potential for abuse and is known to damage brain DA neurons in animals (Seiden & Ricaurte, 1987; Villemagne et al., 1998) and, possibly, humans ( McCann et al., 1998 ).”
BackgroundMDMA ("Ecstasy") and Neurotoxicity
Mithoefer, M. C., Jerome, L., Doblin, R., & Ricaurte, G. A. (2003) · Science · doi:10.1126/science.300.5625.1504 · Cited by 36
Thanos, P. K., Kim, R., Delis, F., Rocco, M. J., Cho, J. A., & Volkow, N. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.12.010 · Cited by 35
Liu, Y., Han, M., Liu, X., Deng, Y., Li, Y., Yuan, J., Lv, R., Wang, Y., Zhang, G., & Gao, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3148-z · Cited by 35
Sabol, K. E., Roach, J. T., Broom, S. L., Ferreira, C. B., & Preau, M. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03244-3 · Cited by 35
Li, S., Yan, S., Bao, Y., Lian, Z., Qu, Z., Ya-ping, W., & Liu, Z. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2335 · Cited by 34
“In addition, the first PET study showed that caudate and putamen DAT ([11C] WIN-35,428) binding was reduced even after 3 years of abstinence from METH (McCann et al., 1998).”
BackgroundMesocorticolimbic monoamine correlates of methamphetamine sensitization and motivation
Lominac, K. D., McKenna, C. L., Schwartz, L. M., Ruiz, P. N., Wroten, M. G., Miller, B. W., Holloway, J. J., Travis, K. O., Rajasekar, G., Maliniak, D., et al. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00070 · Cited by 34
Urban, N., & Martínez, D. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.011 · Cited by 35
Two-Year Outcomes of Treatment for Methamphetamine Use
Brecht, M., Greenwell, L., von Mayrhauser, C., & Anglin, M. D. (2006) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2006.10400605 · Cited by 34
Amphetamine Dependence and Co-Morbid Alcohol Abuse: Associations to Brain Cortical Thickness
Lawyer, G., Bjerkan, P. S., Hammarberg, A., Jayaram‐Lindström, N., Franck, J., & Agartz, I. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-5 · Cited by 33
Striatal dopamine and glutamate receptors modulate methamphetamine-induced cortical Fos expression
Gross, N. B., & Marshall, J. F. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.04.023 · Cited by 33
Metadata
- Authors
- McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A.
- Affiliations
- National Institute of Mental Health (US)
- Johns Hopkins University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 1998-10-15
- Volume
- 18
- Issue
- 20
- Pages
- 8417-8422
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6792853
- OpenAlex
- W2106287416
- Cited by
- 602
- References
- 46
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 10 · 2021: 19 · 2020: 11 · 2019: 12 · 2018: 14 · 2017: 16 · 2016: 16 · 2015: 27 · 2014: 32 · 2013: 38 · 2012: 34
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01da009482-05, 5r01da006275-03)
- National Institute of Mental Health
- National Institute on Drug Abuse (F32DA005707, DA05707, DA09482, DA-06275, R01DA005707)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- methamphetamine, methcathinone, amphetamine abuse, dopamine transporter density, striatum, caudate nucleus, putamen, dopamine neuron loss, Parkinson's disease, psychostimulants, neurotoxicity
- MeSH terms
- Adult, Central Nervous System Stimulants, Brain Chemistry, Carbon Radioisotopes, Carrier Proteins, Cocaine, Female, Humans, Male, Membrane Glycoproteins, Methamphetamine, Middle Aged, Nerve Tissue Proteins, Parkinson Disease, Secondary, Propiophenones, Tomography, Emission-Computed, Neostriatum, Dopamine Uptake Inhibitors, Amphetamine-Related Disorders, Membrane Transport Proteins, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
